SCHEMBL15469504

SCHEMBL15469504

Cc1ccc([C@@]2(N)CCN(C)c3cccnc32)cc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.37
TP53 P04637 2/20 0.33
GAA P10253 2/20 0.33
PDE4B Q07343 2/20 0.33
PDE4D Q08499 2/20 0.33
MAPT P10636 2/20 0.32
AKR1B10 O60218 1/20 0.32
AKR1C4 P17516 1/20 0.32
AKR1C3 P42330 1/20 0.32
AKR1C2 P52895 1/20 0.32
AKR1C1 Q04828 1/20 0.32
AKT1 P31749 3/20 0.31
EGLN1 Q9GZT9 3/20 0.31
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MAP3K14 Q99558 1/20 0.30
GPBAR1 Q8TDU6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467457 0.83 TRPV1 (0.41) TRPV1
SCHEMBL15467456 0.83 TRPV1 (0.41) TRPV1
SCHEMBL15469505 0.83 NOTUM (0.38) TRPV1TP53GAAPDE4BPDE4D
SCHEMBL15469510 0.77 AKR1B10 (0.34) TRPV1PDE4BPDE4DAKR1B10AKR1C4
SCHEMBL15469503 0.76 AKR1B10 (0.34) TRPV1PDE4BPDE4DAKR1B10AKR1C4
SCHEMBL15469508 0.75 AKR1B10 (0.33) TRPV1PDE4BPDE4DAKR1B10AKR1C4
SCHEMBL15469386 0.74 TRPM8 (0.33) PDE4BPDE4DAKR1B10AKR1C4AKR1C3
SCHEMBL15469414 0.74 TRPM8 (0.33) PDE4BPDE4DAKR1B10AKR1C4AKR1C3
SCHEMBL15469507 0.72 PDE4B (0.32) PDE4BPDE4DAKR1B10AKR1C4AKR1C3
SCHEMBL16418722 0.71 AKR1B10 (0.39) PDE4BPDE4DMAPTAKR1B10AKR1C4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPV1 11/4885TP53 4199/4885GAA 780/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPV1 11/4885TP53 4199/4885GAA 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.